Lariam is a registered trademark of Roche Pharmaceuticals.
Malaria prevalence and drug-resistant areas: [3,4]
Chloroquine may no longer be effective chemoprophylaxis in many countries [3,5]
Mefloquine may be ineffective in parts of South America, Africa, and Southeast Asia (Burma, Thailand, and Cambodia) [3,4]
MALARONE offers the shortest duration of use before and after travel.
MALARONE had significantly fewer neuropsychiatric adverse events (AEs) than Lariam (P=0.001) [1]
MALARONE had fewer discontinuations due to adverse events
Prophylaxis dosing for adult and pediatric patients:
Important Safety Information
For prophylaxis: In adults, the most commonly reported adverse events possibly attributable to MALARONE versus placebo were headache (5% vs 7%) and abdominal pain (3% vs 5%); in pediatric patients, headache (14% vs 14%), abdominal pain (31% vs 29%), and vomiting (7% vs 6%).
In a clinical trial, adverse experiences possibly attributable to prophylactic therapy, which occurred in ≥ 5% of subjects receiving MALARONE versus mefloquine as the comparator drug, are listed as follows: MALARONE: diarrhea (8%), dreams (7%), oral ulcers (6%), and abdominal pain (5%) versus mefloquine: dreams (14%), insomnia (13%), dizziness (9%), nausea (8%), diarrhea (7%), headache (7%), and abdominal pain (5%).
MALARONE is contraindicated for prevention of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min). MALARONE is contraindicated in individuals with known hypersensitivity to atovaquone or proguanil HCl or any component of the formulation. Rare cases of anaphylaxis following treatment with MALARONE have been reported.
